GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aprea Therapeutics
The shares of Aprea, an oncology biotech, reflect the potential of its pipeline. The price chart is a classic biotech story, with valuation driven by expectations of clinical trial results.
Share prices of companies in the market segment - General oncology therapy
Aprea Therapeutics is an oncology company developing drugs that reactivate the p53 tumor suppressor protein to fight cancer. We've categorized it as a "General Oncology" company. The chart below shows how investors view this unique scientific approach to cancer treatment.
Broad Market Index - GURU.Markets
Aprea Therapeutics is an oncology company developing drugs that restore the function of tumor suppressor genes. Its scientific approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Aprea compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
APRE - Daily change in the company's share price Aprea Therapeutics
The daily price change of Aprea Therapeutics, Inc. reflects the extreme volatility inherent in oncology companies. This metric measures the sensitivity to clinical trial data from its drugs, serving as a risk assessment element.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Aprea Therapeutics develops new cancer treatments, focusing on restoring the function of tumor suppressor proteins. The oncology biotech sector is extremely volatile. The chart below shows average daily fluctuations in this sector, allowing one to assess APREA's performance in the context of the entire industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Aprea Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aprea Therapeutics
For Aprea Therapeutics, year-over-year performance reflects its focus on developing drugs that target DNA damage in cancer cells. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate could offer a new approach to treating difficult-to-treat cancers.
Annual dynamics of market capitalization of the market segment - General oncology therapy
As an early-stage biotech company, Aprea is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aprea Therapeutics, a biopharmaceutical company focused on oncology, exemplifies how scientific research drives value. Its year-over-year market capitalization dynamics reflect investor expectations for clinical trial results. Success in developing a new drug can lead to explosive growth, defying any macroeconomic turbulence.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aprea Therapeutics
Aprea is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its p53-reactivating drugs prompts an immediate investor reaction.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapies targeting the reactivation of tumor suppressors. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its unique scientific approach is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aprea Therapeutics is an oncology company whose stock price is driven by news about clinical trials and partnerships. The chart shows that monthly price fluctuations are a response to company-specific events, such as data releases, rather than to overall market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aprea Therapeutics
Aprea Therapeutics, a clinical-stage oncology company, exhibits high volatility. Its weekly stock price is almost always a direct reaction to the publication of trial data or regulatory decisions. The chart below is a map of the hopes and risks inherent in the biotech sector.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Aprea Therapeutics is a biotech company focused on oncology. Its shares are highly sensitive to clinical trial news, rather than overall market sentiment. The chart will help you understand whether the weekly performance is a result of industry trends or a reaction to events unique to Aprea.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aprea Therapeutics is a biotech company whose future depends on the success of its oncology clinical trials. Its shares are a classic example of an asset that doesn't correlate with the market. The chart clearly shows how news from the lab triggers movements that defy any market trends.
Market capitalization of the company, segment and market as a whole
APRE - Market capitalization of the company Aprea Therapeutics
Aprea Therapeutics' market capitalization chart is a financial expression of the hopes and disappointments of cancer drug discovery. Its dynamics reflect both the failures of previous drugs and investor confidence in its new developments in molecular "glues." The company's value is a bet that its new scientific approach will succeed where the old one failed.
APRE - Share of the company's market capitalization Aprea Therapeutics within the market segment - General oncology therapy
Aprea Therapeutics's market share in the oncology sector reflects its scientific approach, not its current sales. This clinical-stage company's market cap reflects investors' faith in the potential of its drugs to reactivate tumor suppressor proteins. This represents the weight of a high-risk, yet potentially breakthrough, idea.
Market capitalization of the market segment - General oncology therapy
Here's a chart showing the total value of the entire oncology-focused biotech sector. It's a trillion-dollar market of hope. For Aprea Therapeutics, which develops cancer treatments, the growth of this chart signifies increased investor interest in the industry, making it easier to raise capital for expensive clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aprea Therapeutics develops drugs to reactivate tumor suppressor proteins. Its small market cap is the price of hope for a new approach in oncology. In the overall market, it represents a tiny but concentrated share, representing scientific risk and a potential breakthrough.
Book value capitalization of the company, segment and market as a whole
APRE - Book value capitalization of the company Aprea Therapeutics
Aprea Therapeutics is a biopharmaceutical company focused on oncology. Its book value represents its financial cushion. It consists of cash allocated for clinical trials of new anti-cancer drugs. How has this "war chest" changed? The chart below shows.
APRE - Share of the company's book capitalization Aprea Therapeutics within the market segment - General oncology therapy
Aprea Therapeutics is a biotech company focused on new cancer treatments. Its scientific research requires a resource base, including modern laboratories and equipment for the research and development of oncology drugs. The chart shows the company's share of the physical R&D infrastructure in this biopharma segment.
Market segment balance sheet capitalization - General oncology therapy
Aprea Therapeutics is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Aprea focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Aprea Therapeutics' book value isn't derived from its factories, but from its financial and material resources for fighting cancer: capital for clinical trials and laboratory equipment. This metric reflects the company's tangible "arsenal" dedicated to scientific research. The chart illustrates its scale in the world of biotech.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aprea Therapeutics
Aprea Therapeutics is a biopharmaceutical company focused on oncology. Its market capitalization is a barometer of investor hopes for the success of its clinical trials. Its book value is minimal, and its market valuation is the option price for a potential breakthrough in cancer treatment.
Market to book capitalization ratio in a market segment - General oncology therapy
Aprea Therapeutics is a biotech company developing cancer treatments. Its market capitalization on this chart represents investors' net bet on the future success of its clinical trials. This metric reflects the vast gap between its current assets (primarily cash) and the potential future value of the drug.
Market to book capitalization ratio for the market as a whole
Biotech companies like Aprea Therapeutics thrive on the hope of scientific breakthroughs. Their market valuation is largely unrelated to their book value, as their main asset is patents for potential cancer drugs. This chart shows the risk premium and future returns that investors factor into their valuations of innovative companies.
Debts of the company, segment and market as a whole
APRE - Company debts Aprea Therapeutics
Aprea Therapeutics, a biopharmaceutical company focused on oncology, relies entirely on external capital to fund its clinical research. Debt is a vital tool for advancing development through the clinical trials stage. This chart shows how the company raises resources for its long-term and risky scientific mission.
Market segment debts - General oncology therapy
Aprea Therapeutics is a biotech company focused on developing a new class of cancer treatments. With no commercial products, its operations are entirely dependent on external funding. This chart shows how the company uses its capital to advance its candidates through expensive clinical trials, reflecting its financial strategy in the race for breakthroughs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aprea Therapeutics
Aprea Therapeutics develops anticancer drugs that restore the function of the p53 tumor suppressor gene. This cutting-edge approach requires massive investments in clinical trials. This chart shows how the company uses debt to finance its high-risk but potentially breakthrough oncology research.
Market segment debt to market segment book capitalization - General oncology therapy
Aprea Therapeutics is a biopharmaceutical company focused on developing cancer treatments. Clinical trials are a long and expensive process. This chart shows how the company finances its operations. It compares its debt structure to the overall biotech market cap, reflecting its high financial risk.
Debt to book value of all companies in the market
Aprea Therapeutics develops new cancer treatments aimed at reactivating the p53 tumor suppressor gene. Oncology research requires huge, long-term, and risky investments. How heavily does the company rely on debt to finance its breakthrough research? This graph of total debt in the economy helps assess its financial strength.
P/E of the company, segment and market as a whole
P/E - Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments by reactivating the p53 tumor suppressor gene. This chart reflects the high risks and expectations associated with its scientific approach. Its valuation is highly dependent on clinical trial results.
P/E of the market segment - General oncology therapy
Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer treatments by reactivating the p53 tumor suppressor. This chart illustrates the average valuation in the oncology development sector, where investors are betting on innovative approaches to cancer treatment while appreciating the high risks of clinical trials.
P/E of the market as a whole
Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer treatments by reactivating tumor suppressors. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether APREA's valuation is based on faith in its unique scientific approach or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aprea Therapeutics
Aprea Therapeutics is a biotech company focused on developing drugs that restore the anti-tumor function of the p53 protein, known as the "guardian of the genome." This chart reflects investor expectations for the success of their clinical trials, demonstrating the market's confidence in this innovative approach to cancer treatment.
%20P%2FE%20Aprea%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aprea-Therapeutics&v=1772604872270 "Chart of the company's future (projected) P/E Aprea Therapeutics")
Future (projected) P/E of the market segment - General oncology therapy
Aprea Therapeutics is a biotech company developing cancer treatments. Its valuation is based almost entirely on expectations of future clinical trial success. This chart reflects speculative profitability forecasts for the sector, allowing one to assess the level of investor confidence in Aprea's scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772604872290 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Aprea Therapeutics is a clinical-stage biotech company whose value is determined by the prospects of its oncology developments. This overall market sentiment chart is important because it reflects investor willingness to fund long-term, risky scientific projects, assessing future potential rather than current financial performance.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772604872305 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aprea Therapeutics
Aprea Therapeutics is a biotech company focused on developing a new class of anti-cancer drugs that restore tumor suppressor gene function. Its financial performance primarily reflects clinical research expenditures. This chart shows the amount of research investment that could lead to breakthroughs in cancer treatment and future profits.
Profit of companies in the market segment - General oncology therapy
Aprea Therapeutics is a biopharmaceutical company focused on developing new cancer treatments by reactivating anti-tumor proteins. Its potential lies in the success of clinical trials. This chart illustrates the overall picture in the oncology sector, where scientific breakthroughs can lead to the creation of revolutionary drugs and high profits, despite the enormous risks.
Overall market profit
Aprea Therapeutics is a biotechnology company focused on developing drugs for the treatment of oncology. Its value and prospects are determined solely by clinical trial results and scientific breakthroughs. The overall economic situation, illustrated by this chart, does not directly impact the demand for effective cancer treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aprea Therapeutics
Aprea Therapeutics is a biotechnology company developing cancer treatments by reactivating tumor suppressor proteins. Future revenue is entirely dependent on the success of clinical trials and regulatory approval. This chart reflects speculative market expectations regarding the scientific breakthrough and commercial potential of its oncology drugs.
%20profit%20of%20the%20company%20Aprea%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aprea-Therapeutics&v=1772604872411 "Graph of future (projected) profit of the company Aprea Therapeutics")
Future (predicted) profit of companies in the market segment - General oncology therapy
Aprea Therapeutics is developing new cancer treatments aimed at restoring the function of the p53 tumor suppressor gene. This is an innovative approach in oncology. The company's success depends entirely on the results of clinical trials. This chart shows overall revenue projections for the oncology sector, helping to assess the potential of Aprea's breakthrough science.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772604872455 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Aprea Therapeutics is a biotech company focused on developing drugs for the treatment of oncology. Its success depends on research results and capital raising. This graph, reflecting market profit expectations, influences the investment climate. Growing optimism increases investor willingness to finance risky biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772604872499 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biotech company focused on oncology. Revenue, if any, is minimal and doesn't reflect potential. This chart represents almost pure expectations. Any value is not an estimate of current sales, but rather a reflection of investor confidence in the company's scientific platform and the future commercial success of its anticancer drugs.
P/S market segment - General oncology therapy
Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer treatments by reactivating the p53 tumor suppressor protein. Their approach could hold the key to treating a wide range of oncological diseases. This chart shows the average revenue estimate for the sector, reflecting investor expectations for innovative oncology platforms.
P/S of the market as a whole
Aprea Therapeutics is a biopharmaceutical company focused on developing cancer treatments by reactivating anti-tumor genes. For such companies, valuation is loosely tied to current revenue. This chart highlights that their value is driven by their R&D potential, which contrasts sharply with the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aprea Therapeutics
Aprea Therapeutics is a biopharmaceutical company focused on developing cancer treatments by reactivating anti-tumor proteins. The company's clinical-stage revenue estimates reflect investor confidence. This chart shows the market's confidence in Aprea's scientific approach and the commercial potential of its lead oncology drug candidates.
%20P%2FS%20Aprea%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aprea-Therapeutics&v=1772604872787 "The graph of the company's future (projected) P/S Aprea Therapeutics")
Future (projected) P/S of the market segment - General oncology therapy
Aprea Therapeutics is a biotech company focused on developing drugs that restore the anti-tumor activity of the p53 protein. This chart reflects how investors assess the company's future revenues relative to the oncology sector. It demonstrates the market's confidence in the scientific potential of its approach and the potential to create a new class of cancer treatments.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772604872825 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Aprea Therapeutics is developing new cancer treatments aimed at restoring the function of the p53 tumor suppressor gene. The company's future depends entirely on the success of its clinical trials. This market outlook chart reflects investor confidence in breakthrough oncology technologies and their long-term commercial potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772604872890 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aprea Therapeutics
The graph illustrates the revenue of Aprea Therapeutics, a biopharmaceutical company developing drugs for the treatment of oncology. Since its products are in clinical trials, revenue may be zero or consist of payments from partners. The dynamics reflect progress in research and the ability to attract funding for development.
Sales of companies in the market segment - General oncology therapy
Aprea Therapeutics is developing novel cancer treatments aimed at reactivating the p53 tumor suppressor protein. Being in the clinical stage, the company does not yet have stable sales revenue. Its future revenue structure will depend on which of its innovative drug candidates achieves commercial success first.
Overall market sales
Aprea Therapeutics is a biopharmaceutical company focused on developing new cancer treatments. Its success depends solely on the results of clinical trials and the scientific potential of its developments. This overall economic performance schedule has no direct impact on the company, whose mission is to combat cancer, where demand is driven by medical need.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aprea Therapeutics
Aprea Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel cancer treatments aimed at reactivating the p53 tumor suppressor gene. Future revenues are dependent on the success of clinical trials. This chart reflects analysts' forecasts for potential sales of the company's drugs should they be approved and enter the oncology market.
%20sales%20of%20the%20company%20Aprea%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aprea-Therapeutics&v=1772604872999 "Schedule of future (projected) sales of the company Aprea Therapeutics")
Future (projected) sales of companies in the market segment - General oncology therapy
Aprea Therapeutics is developing new cancer treatments aimed at restoring the function of tumor suppressor genes. This chart shows revenue forecasts for the entire oncology market. Is growth expected due to breakthrough technologies and new drugs? This reflects the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772604873017 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Aprea Therapeutics is a biotechnology company focused on developing cancer treatments. Its success depends on clinical trial results, regulatory approvals, and scientific progress. The overall economic trends reflected in this chart do not directly impact its core business or patient demand for effective oncology drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772604873045 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aprea Therapeutics
Aprea Therapeutics is a biotech company focused on developing novel cancer treatments by reactivating anti-tumor proteins. This chart reflects its financial performance at the clinical trial stage. Profitability is a future goal, while current metrics demonstrate the level of investment in research that could lead to the development of breakthrough drugs.
Market segment marginality - General oncology therapy
Aprea Therapeutics is a clinical-stage biotechnology company focused on developing drugs for the treatment of oncology. The company has no commercial revenue and incurs significant R&D expenses. This chart reflects its current financial position, with future profitability entirely dependent on the success of clinical trials and the potential commercialization of its drugs.
Market marginality as a whole
Aprea Therapeutics' cancer drug development depends on long-term funding and the state of the healthcare system. This total return chart reflects the economic climate, which influences investor willingness to invest in capital-intensive biotech projects and the market's ability to pay for new treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Aprea Therapeutics
Aprea Therapeutics is a biotech company developing cancer drugs. Its small but highly skilled staff consists of scientists and clinicians. This graph shows how the team grows as its drugs progress through clinical trials. This increase in staff is a key signal of progress in research and approaching important milestones.
Share of the company's employees Aprea Therapeutics within the market segment - General oncology therapy
Aprea Therapeutics is a biotech company focused on developing new cancer treatments. Its primary asset is the intellectual capital of its team of scientists and researchers working in its laboratories. This chart shows the company's market share in the oncology sector, reflecting the scale of its R&D activities and its focus on science-intensive processes.
Number of employees in the market segment - General oncology therapy
Aprea Therapeutics is focused on developing anticancer drugs that restore the activity of the tumor suppressor protein p53. The chart reflects activity in the general oncology sector. The growing number of scientists in this field underscores the enormous investment in discovering new mechanisms to fight cancer, and Aprea is working on one of the most fundamental approaches.
Number of employees in the market as a whole
Aprea Therapeutics is a biotech company working on cancer treatments. Its staff grows or shrinks based on clinical trial results and funding, not the state of the economy. This chart reflects general trends, but in the world of Aprea, every new hire is a bet on a scientific breakthrough that can change lives, regardless of market conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aprea Therapeutics (APRE)
Aprea Therapeutics is a biotech company focused on developing new cancer treatments. In this sector, market value is almost entirely dependent on intellectual property. This chart illustrates the enormous premium the market places on the potential of their R&D pipeline per highly qualified scientist.
%20of%20the%20company%20Aprea%20Therapeutics%20(APRE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aprea-Therapeutics-APRE&v=1772604873265 "Chart of market capitalization per employee (in thousands of dollars) of the company Aprea Therapeutics (APRE)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Aprea Therapeutics (APRE) is a biotech company developing a new generation of cancer drugs. In this industry, market capitalization per employee is a measure of intellectual capital. Often, a small team of scientists generates billions of dollars in value through drug patents, which reflects this metric relative to the sector.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772604873269 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Aprea Therapeutics is a biotech company developing cancer treatments. Its market capitalization is largely unrelated to its headcount. This chart demonstrates that the market values the company's scientific potential rather than its current operations. The success of a single clinical trial can generate billions of dollars in value, which is reflected in its high valuation.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772604873304 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aprea Therapeutics (APRE)
Aprea is a clinical-stage biotech company working on cancer drugs. For such R&D companies, this graph often shows the *loss* per employee. It reflects not inefficiency, but the intensity of investment. Each scientist is a cost center, burning through investor capital for the sake of future scientific breakthroughs and commercialization.
%20Chart%20Aprea%20Therapeutics%20(APRE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aprea-Therapeutics-APRE&v=1772604873317 "Company Profit Per Employee (in thousands of dollars) Chart Aprea Therapeutics (APRE)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Aprea Therapeutics is a biotech company focused on oncology research. In this sector, employee productivity is cyclical: years of R&D can be unprofitable, but a single successful drug can recoup all costs many times over. The graph illustrates the financial return per employee, which is especially important for comparison with competitors at different stages of research.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772604873336 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Aprea Therapeutics is a biotech company working on a new generation of cancer drugs. In this sector, profitability per employee is the future. For years, the company has been burning through capital on R&D. This chart, showing the average market profit per employee, only highlights how different the biotech model, where 10 scientists can create a billion-dollar product (or nothing), is from the rest of the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772604873383 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aprea Therapeutics (APRE)
Aprea Therapeutics is a clinical-stage biotech company developing oncology drugs. Currently, revenue per employee may be minimal. This graph is important for assessing the future: if the drug is successful and approved, this metric will skyrocket, reflecting the enormous value of the intellectual property created by the team of scientists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aprea-Therapeutics-APRE&v=1772604873410 "Sales chart per company employee Aprea Therapeutics (APRE)")
Sales per employee in the market segment - General oncology therapy
Aprea Therapeutics is a clinical-stage biotech company working on cancer treatments. They don't yet have commercial revenue. In this context, this chart, which reflects the average yield in the sector, serves as a benchmark for Aprea. It shows how high their labor costs (burn rate) are compared to competitors and what their future productivity should be.
Sales per employee for the market as a whole
Aprea Therapeutics is a biotech company focused on developing new cancer treatments. At this stage, their business is not sales, but science. This indicator reflects the intensive R&D phase. Revenue, if any, is minimal and generated not by the product but by the team of scientists working on the next breakthrough.
Short shares by company, segment and market as a whole
Shares shorted by company Aprea Therapeutics (APRE)
Aprea Therapeutics (APRE) is a biotech company developing cancer treatments. It's a sector with binary risk: either resounding success or complete failure. This chart shows the volume of short positions. The high short position is typical for biotechs and reflects the bears' bet that clinical trials of the company's key drug will not yield the expected results.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aprea-Therapeutics-APRE&v=1772604873540 "Short Shares Chart for the Company Aprea Therapeutics (APRE)")
Shares shorted by market segment - General oncology therapy
Aprea Therapeutics (APRE) is a biotech company working on a complex problem: reactivating tumor suppressor proteins (p53) to treat cancer. This chart aggregates short positions across the entire oncology biotech sector. It reflects the general investor skepticism regarding the risks of clinical trials and the high mortality rate of projects in this sector.
Shares shorted by the overall market
Aprea (APRE) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing APRE won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aprea Therapeutics (APRE)
Aprea Therapeutics (APRE) is a biotech focused on reactivating p53, a key tumor suppressor protein, for cancer treatment. It's an important but challenging target. This chart measures the rate of price change. It shows when the stock is "overheated" (above 70) in anticipation of data or "oversold" (below 30) after disappointing results.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aprea-Therapeutics-APRE&v=1772604873706 "RSI 14 indicator chart for the company's stock Aprea Therapeutics (APRE)")
RSI 14 Market Segment - General oncology therapy
Aprea Therapeutics is a biopharmaceutical company focused on developing cancer treatments. Its approach is aimed at reactivating the tumor suppressor protein p53. This chart shows the overall sentiment in the oncology biotech sector. It helps us understand whether APREA's momentum is driven by its clinical data or is a general "wave" across the industry.
RSI 14 for the overall market
Aprea Therapeutics (APRE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APRE (Aprea Therapeutics)
Aprea Therapeutics is a biotech company focused on developing drugs that reactivate the p53 tumor suppressor protein. This chart shows the average target price. Analysts' estimates are based on clinical data for their candidates and the potential of this mechanism for cancer treatment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APRE-Aprea-Therapeutics&v=1772604873815 "A chart showing analyst consensus forecasts for the expected stock price. APRE (Aprea Therapeutics)")
The difference between the consensus estimate and the actual stock price APRE (Aprea Therapeutics)
Aprea is a biotech company focused on developing drugs that reactivate the p53 tumor suppressor gene. This is the "Holy Grail" of oncology. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this daunting scientific challenge.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APRE-Aprea-Therapeutics&v=1772604873824 "A chart showing the difference between the consensus forecast and the actual stock price. APRE (Aprea Therapeutics)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Aprea Therapeutics is a biotech company developing targeted cancer treatments by reactivating the p53 tumor suppressor protein. This chart shows overall expectations for the general oncology sector, reflecting experts' confidence in the success of this R&D approach.
Analysts' consensus forecast for the overall market share price
Aprea Therapeutics (APRE) is a clinical-stage biopharmaceutical company focused on cancer treatment. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aprea Therapeutics
Aprea is a p53 savior. They're a biotech company whose specialty is the R&D of drugs that reactivate the p53 guardian gene (the main cancer defender), which is defective in many tumors. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - General oncology therapy
Aprea Therapeutics (APRE) is an oncology company targeting the holy grail of cancer—the p53 gene. They are developing drugs that reactivate this powerful tumor suppressor gene, causing cancer cells to self-destruct. This chart shows the segment's average index, helping to assess how this complex yet disruptive strategy compares to the average.
The AKIM Index for the overall market
Aprea Therapeutics is a biotech company developing synthetically engineered lethal therapies for cancer (ATR and WEE1 inhibitors). This chart, which reflects the market average, provides a macro backdrop. It helps assess how APREA, the company's scientific history, compares to overall economic trends.
